Growth Metrics

Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)

Travere Therapeutics' Cash from Discontinued Operations history spans 3 years, with the latest figure at 7089000.0 for Q4 2024.

  • For Q4 2024, Cash from Discontinued Operations fell 16.21% year-over-year to 7089000.0; the TTM value through Sep 2025 reached 7089000.0, down 9.7%, while the annual FY2024 figure was 7451000.0, 116.44% down from the prior year.
  • Cash from Discontinued Operations reached 7089000.0 in Q4 2024 per TVTX's latest filing, down from 50000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 22064000.0 in Q4 2022 to a low of 7089000.0 in Q4 2024.
  • Average Cash from Discontinued Operations over 3 years is 6661000.0, with a median of 50000.0 recorded in 2024.
  • Peak YoY movement for Cash from Discontinued Operations: crashed 127.65% in 2023, then decreased 16.21% in 2024.
  • A 3-year view of Cash from Discontinued Operations shows it stood at 22064000.0 in 2022, then plummeted by 127.65% to 6100000.0 in 2023, then dropped by 16.21% to 7089000.0 in 2024.
  • Per Business Quant, the three most recent readings for TVTX's Cash from Discontinued Operations are 7089000.0 (Q4 2024), 50000.0 (Q3 2024), and 309000.0 (Q2 2024).